用于COVID-19患者的吸入性皮质类固醇:随机对照试验的系统审查和元分析
Chin-Wei Hsu1, Mei-Chuan Lee2, Yi-Ming Hua3
1Department of Pharmacy, Chi Mei Medical Center, Tainan, Taiwan; School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
概括
吸入性皮质类固醇 (ICS) 可能有助于缓解COVID-19的症状,特别是布塞尼德. 然而,ICS治疗并没有显著减少COVID-19患者的紧急护理访问,住院或死亡.
科学领域:
- 肺部病理学 肺部病理学
- 传染性疾病 传染性疾病
- 临床试验 临床试验
背景情况:
- 关于吸入性皮质类固醇 (ICS) 治疗COVID-19患者的疗效存在不一致的发现.
- 随机对照试验 (RCT) 已经探索了ICS的使用,但结果各不相同.
研究的目的:
- 系统地评估ICS在COVID-19患者中的临床疗效和安全性.
- 综合来自RCT关于ICS治疗COVID-19的证据.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane等) 进行了全面的文献搜索. 在2023年6月10日之前.
- 仅包括评估ICS对COVID-19的临床疗效和安全性的RCT.
- 十一个RCT符合纳入标准.
主要成果:
- 在第14天,ICS使用与显著更高的症状缓解率相关 (RR,1.13;95% CI,1.04-1.23).
- 在紧急护理,急诊室访问或住院治疗的综合结果中没有发现显著差异 (RR,0.43;95% CI,0.08-2.48).
- 在28日,ICS使用显示死亡风险降低不显著 (RR,0.82;95% CI,0.43-1.56).
结论:
- 额外的ICS,特别是吸入的布迪索尼德,可能有助于缓解COVID-19患者的症状.
- ICS治疗没有显著降低紧急护理,住院或死亡的风险.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
299
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
299
01:23Inhaled Medications
309
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
309
01:20Asthma: Pathogenesis and Management
446
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
446
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K